Physician profile
David Snow
NPI 1699228932
$3,626.37
in general payments reported to CMS, 2019-2025
28 companies · $872 in 2025
The $872 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $188 · 2021: $165 · 2022: $253 · 2023: $219 · 2024: $927 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,916.44 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $501.21 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $459.33 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $440.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $371.24 | 2019-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $316.72 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.21 | 2021-2025 | Caplyta |
| Abbvie INC. | $196.27 | 2021-2025 | Vraylar |
| Alkermes, INC. | $185.43 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $154.24 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $90.43 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $86.48 | 2019-2022 | |
| Axsome Therapeutics, INC. | $85.27 | 2024-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $63.63 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $60.94 | 2023-2024 | Jornay Pm |
| Sage Therapeutics, LLC | $53.21 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $50.09 | 2019-2020 | |
| Indivior INC. | $43.88 | 2020-2023 | Perseris |
| Avadel Cns Pharmaceuticals, LLC | $34.00 | 2025 | Lumryz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.66 | 2019-2025 | |
| Ucb, INC. | $32.64 | 2024 | Nayzilam |
| Corium, LLC | $32.35 | 2022-2024 | Azstarys |
| Tris Pharma INC | $29.78 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $28.48 | 2021 | |
| Merck Sharp & Dohme LLC | $16.69 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.13 | 2021 | |
| Shire North American Group INC | $15.40 | 2019 | |
| Almatica Pharma LLC | $13.05 | 2022 | |
| Neuronetics, INC. | $10.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.